Patents by Inventor Michael James Genin

Michael James Genin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds and related methods
    Patent number: 11919868
    Abstract: Provided herein are compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof. Also provided are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: March 5, 2024
    Assignee: RECURSION PHARMACEUTICALS, INC.
    Inventors: Michael James Genin, Joseph Carpenter, Carl Brooks
  • HETEROCYCLIC COMPOUNDS AND RELATED METHODS
    Publication number: 20220380323
    Abstract: The present disclosure describes compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof, wherein all of the variables are as defined herein. This disclosure also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 1, 2022
    Inventors: Michael James Genin, Joseph Carpenter, Carl Brooks
  • [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes
    Patent number: 11401274
    Abstract: The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 2, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Cynthia Darshini Jesudason, Qing Shi
  • [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives
    Patent number: 11180503
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 23, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
    Publication number: 20210147437
    Abstract: The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.
    Type: Application
    Filed: August 3, 2018
    Publication date: May 20, 2021
    Inventors: Michael James Genin, William Glen Holloway, Cynthia Darshini Jesudason, Qing Shi
  • [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-6(5H)-ONE DERIVATIVES
    Publication number: 20200123154
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 23, 2020
    Applicant: Eli Lilly and Company
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • METHODS FOR TREATING KIDNEY DISORDERS
    Publication number: 20170354645
    Abstract: Provided are methods and formulations for treating kidney disorders in man and animals, which include the use of a compound of the Formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 24, 2015
    Publication date: December 14, 2017
    Inventors: Asim Bikash DEY, Michael James GENIN, Laura Frey MICHAEL
  • 1,2-BENZOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISORDERS
    Publication number: 20170246166
    Abstract: The present invention provides 1,2-benzothiazole compounds particularly useful in the treatment of diabetic nephropathy and other chronic kidney disorders and other diabetic complications.
    Type: Application
    Filed: November 13, 2015
    Publication date: August 31, 2017
    Inventors: Michael James Genin, I, William Glen Holloway, Mark David Rekhter
  • Compounds and methods for modulating FXR
    Patent number: 8153624
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • Compounds and methods for modulating FXR
    Patent number: 8106077
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
  • Compounds and methods for modulating FX-receptors
    Patent number: 7863302
    Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • FXR agonists
    Patent number: 7846960
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20100152166
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Application
    Filed: July 11, 2008
    Publication date: June 17, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • FXR AGONISTS
    Publication number: 20090270460
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: October 29, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20090093524
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: April 9, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • Compounds and Methods for Modulating Fx-Receptors
    Publication number: 20080306125
    Abstract: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: February 2, 2007
    Publication date: December 11, 2008
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites